An extremely promising breakthrough was made by a laboratory antigen discovery research team, that showed an effectiveness level of up to 99% for vaccine delivery coupled with the E140 antigen. Research to date has been supported by the U.S. Government: Navy Medical Research Center, Army Walter Reed Army Institute of Research, Bill and Melinda Gates Foundation, CAMRIS International, and others. This invention provides polypeptides useful as antigens expressed at the pre-erythrocytic stage of the malaria parasite. The antigens can be utilized to induce an immune response and sterile protection against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other recombinant protein expression systems delivered as a vaccine formulation. This research led to the issuance of an E140 patent in the U.S. and other countries.
As owner of the E140 patent and as an organization committed to promoting public health through proven solutions, Day Life Sciences seeks to work with funding entities (including non-profit, university, governmental, and private investment entities) to integrate the E140 technology into ongoing malaria vaccine research and development efforts.